Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis

Table 1 Biochemical parameters of the different treatment groups

Group	ALT (U/L)	AST (U/L)	Bilirubin (mg/dL)	Albumin (g/L)	BUN (mmol/L)	Scr (μmol/L)
Control (n = 8)	43.3 ± 7.7	124 ± 14	0.3 ± 0.1	34.1 ± 3.4	8.7 ± 1.2	22.4 ± 4.0
OVX + CCl4 (n = 6)	166 ± 10.1ab	439 ± 19ab	3.4 ± 0.3ab	21.5 ± 2.8ab	16.7 ± 1.8ab	35.0 ± 4.7ab
OVX + CCl4 + DPN (n = 7)	86.1 ± 8.7a	211 ± 15a	1.7 ± 0.2a	31.0 ± 3.3	9.6 ± 1.5	24.9 ± 4.5
OVX + CCl4 + DPN + PHTPP (n = 6)	168 ± 10.2ab	436 ± 23ab	3.3 ± 0.4ab	20.8 ± 2.0ab	16.5 ± 2.1ab	37.5 ± 4.6ab

^aP < 0.05 vs control group;

^bP < 0.05 vs DPN group. OVX: Ovariectomized; SVR: Systemic vascular resistance; DPN: Diarylpropionitrile.

Table 2 In vivo hemodynamic data of the four treatment groups

Parameter	Control	OVX + CCl4	OVX + CCl4 + DPN	OVX + CCl4 + DPN + PHTPP
PP (mmHg)	7.5 ± 1.1	14.9 ± 1.6a,c	11.0 ± 1.3a	14.6 ± 1.5a,c
CO (mL/min per 100 g)	19.3 ± 2.4	32.2 ± 5.0a,c	25.7 ± 4.0a	31.4 ± 5.4a,c
MAP (mmHg)	120.6 ± 14.2	82.1 ± 12.2a	95.7 ± 14.0a	89.5 ± 13.3a
TPR (mmHg/mL/min per 100 g)	6.0 ± 0.9	2.6 ± 0.3a	3.1 ± 0.7a	2.9 ± 0.6a
PVI (mL/min per 100 g)	2.1 ± 0.3	4.8 ± 0.8a,c	3.0 ± 0.4a	4.4 ± 0.6a,c
SVR (mmHg/mL/min per 100 g)	55.5 ± 8.5	15.0 ± 2.3a,c	31.7 ± 3.7a	16.8 ± 1.5a,c
PSS (%)	0.2 ± 0.1	50.5 ± 6.3a,c	27.9 ± 4.9a	48.1 ± 6.1a,c
IHVR (mmHg/mL/min per 100 g)	1.5 ± 0.2	3.2 ± 0.6a,c	2.2 ± 0.3a	3.0 ± 0.5a,c

^aP < 0.05 vs control group; ^bP < 0.05 vs DPN group. OVX: Ovariectomized; SVR: Systemic vascular resistance; DPN: Diarylpropionitrile.